StageZero Life Sciences Company Description
StageZero Life Sciences Ltd., a vertically integrated healthcare company, develops and commercializes proprietary molecular diagnostic tests for the early detection of diseases and personalized health management with a primary focus on cancer-related indications in North America and Western Europe.
Its proprietary platform technology is Sentinel Principle, which identifies RNA-based biomarkers from whole blood.
The company’s lead product is Aristotle, a mRNA-based multi-cancer panel test for for the detection of multiple discrete cancers from a single sample of blood.
It also offers ColonSentry, a blood test to determine an individual’s current risk for having colorectal cancer; Prostate Health Index, a screening test for prostate cancer; BreastSentry, a test to determine a woman’s risk for developing breast cancer; and COVID-19 Tests.
The company is based in Richmond Hill, Canada.
| Country | Canada |
| Industry | Diagnostics & Research |
| Sector | Healthcare |
| Employees | 40 |
| CEO | James Howard-Tripp |
Contact Details
Address: 70 East Beaver Creek Road Richmond Hill, Ontario L4B 3B2 Canada | |
| Website | stagezerolifesciences.com |
Stock Details
| Ticker Symbol | SZLSF |
| Exchange | OTCMKTS |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| ISIN Number | CA8525403017 |
| SIC Code | 8011 |
Key Executives
| Name | Position |
|---|---|
| James R. Howard-Tripp | Executive Chairman and Chief Executive Officer |
| Dr. Choong-Chin Liew Ph.D. | Co-Founder |
| Warren Whitehead C.M.A., CPA | Chief Accountant |